In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp.

Journal of Chemotherapy

Volumn 19, Issue 5, 2007, Pages 514-518

  Barchiesi, F ^a   Giacometti, Andrea ^a,c   Cirioni, O ^a   Arzeni, D ^a   Kamysz, W ^b   Silvestri, C ^a   Licci, A ^a   Marigliano, A ^a   Della Vittoria, A ^a   Nadolski, P ^b   Lukasiak J ^b   Scalise, G ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c Ospedale Regionale Torrette   (Italy)

Author keywords

Antimicrobial peptides; Candida spp.; IB 367; Synergy

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; IB 367;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; DRUG POTENTIATION; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN;

EID: 36549030312     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.5.514     Document Type: Article

References (18)

1. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42:4419-4431.
2. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population- based active surveillance program. J Clin Microbiol 2004; 42:1519-1527.
3. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-251.
4. Cannon M. Antimicrobial peptides. A family of wound healers. Nature 1987; 328:478.
5. Hancock REW, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43:1317-1323.
6. Chen J, Falla TJ, Liu H, et al. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers 2000; 55:88-98.
7. Cho Y, Turner JS, Dinh NN, Lehrer RI. Activity of protegrins against yeast-phase Candida albicans. Infect Immun 1998; 66:2486-2493.
8. Hancock RE, Scott MG. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci USA 2000; 97:8856-8861.
9. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J Pept Protein Res 1990; 35: 161-214.
10. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M-27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, Pa 2002.
11. Barchiesi F, Spreghini E, Tomassetti S, Arzeni D, Giannini D, Scalise G. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob Agents Chemother 2005; 49:4989-4992.
12. Canton E, Peman J, Gobernado M, Viudes A, Espinel-Ingroff A. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill and E-test methods. Antimicrob Agents Chemother 2005; 49:1593-1596.
13. Barchiesi F, Falconi Di Francesco L, Scalise G. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob Agents Chemother 1997; 41:1812-1814.
14. Barchiesi F, Spreghini E, Tomassetti S, et al. Effects of caspofungin aginst Candida guillermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006; 50:2719-2727.
15. Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004; 17:268-280.
16. Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1999; 1462:11-28.
17. Huttner KM, Bevins CL. Antimicrobial peptides as mediators of epithelial host defense. Pediatr Res 1999; 45:785-794.
18. Reddy KV, Yedery, RD, Aranha C. Antimicrobial peptides: premises and promises. Intern J Antimicrob Agents 2004; 24:536-547.